AI illustration · not actual product photoDetails from the source.
This catalogue entry records Adipotide, 5 mg × 10 vials (SKU AP5), using the supplied source listing. The cited dossier describes: Preclinical research examined targeted disruption of white-adipose-tissue vasculature. A nonhuman-primate study reported changes in fat mass and insulin resistance. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- AP5
- Source specification
- 5mg*10vials
- Source document
- PriceList(1).pdf, page 1
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
The exact catalogue label is “Adipotide” (SKU AP5; *10vials; listed price 165 per 10 vials, currency unstated). Published research uses this name for an engineered peptide-based peptidomimetic, rather than a naturally occurring peptide. The catalogue label does not establish that this specific vial contains the molecule described in the literature. Its manufacturing or regulatory category cannot be verified from the supplied materials.
Biological mechanism
In the cited animal study, the research peptidomimetic combines a cyclic motif reported to bind prohibitin on vessels supplying white adipose tissue with a cell-penetrating, pro-apoptotic sequence. The proposed mechanism is targeted disruption of endothelial-cell mitochondria, apoptosis, and reduced vascular support to white fat. This is a reported mechanism for the studied molecule, not a verified mechanism for the AP5 vial. [1]
Research focus
Preclinical research examined targeted disruption of white-adipose-tissue vasculature. A nonhuman-primate study reported changes in fat mass and insulin resistance. A registered Phase 1 study investigated PROHIBITIN-TP01 in patients with metastatic prostate cancer and obesity, with stated focus on dose tolerance and safety. [1] [2]
Potential applications in the evidence
Potential applications investigated in the evidence are limited to animal research concerning white-fat reduction and metabolism, and a human Phase 1 safety/dose-tolerance study in metastatic prostate cancer patients with obesity. The trial record does not establish treatment efficacy for obesity or cancer, and animal findings do not demonstrate human benefit. [1] [2]
Human evidence
ClinicalTrials.gov records a first-in-human Phase 1 study of PROHIBITIN-TP01, terminated at the principal investigator’s request, with actual enrollment of four and no posted results. The record establishes a registered study but does not allow assessment of its outcomes. Human efficacy, weight-loss effects, and a reliable human safety profile have not been established in the sources reviewed. [2]
Known and potential effects
In nonhuman primates, the published study reported increased urine output; mild dehydration at the highest tested levels; elevated serum creatinine; lower phosphorus and potassium; glucosuria, proteinuria, and renal epithelial cells in urine; and dose-related renal tubular degeneration or necrosis in toxicology assessments. Many changes improved in recovery, though mild residual creatinine elevation or urinary glucose occurred in individual animals. These are animal findings, not established human adverse effects or verified properties of AP5. [1]
Safety and contraindications
Renal tubular injury and altered kidney function are material concerns in the animal evidence. The human trial record planned kidney-function monitoring, but has no posted results. Human adverse-effect rates, contraindications, and interaction risks therefore cannot be determined from the reviewed sources. No approved product label was identified to define contraindications or establish safety. The animal findings should not be presented as a complete or predictive human safety profile. [1] [2]
U.S. FDA / regulatory status
The ClinicalTrials.gov record describes PROHIBITIN-TP01 as investigational and not FDA-approved or commercially available when last updated. The official Drugs@FDA database covers many FDA-approved drugs; no FDA approval for Adipotide or for this specific AP5 vial was verified in the sources reviewed. Approval or investigational status associated with a studied compound does not transfer to a supplier-specific vial. The catalogue does not identify its manufacturer, formulation, lot, jurisdiction, or approval documentation. The supplied sources do not establish that the item is compounded or research-only. [2] [3]
Evidence limitations
The cited efficacy and safety evidence is predominantly animal research, including nonhuman primates. The small registered human study was terminated and has no posted results, so outcomes cannot be assessed. The catalogue provides no manufacturer, sequence or other chemical identity confirmation, formulation source, lot, independent testing, jurisdiction, or approval documentation. Equivalence between AP5 and the research compound remains unverified. [1] [2]
Supporting sources
- A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys Science Translational Medicine; full text hosted by PubMed Central, U.S. National Library of Medicine · Peer-reviewed primary animal study. Supports: Published research molecule classification and proposed mechanism; animal research findings and renal safety signals. Does not verify the composition or properties of the catalogue vial.
- A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity ClinicalTrials.gov, U.S. National Library of Medicine · Official clinical trial registry record. Supports: Registered human study purpose, Phase 1 design, termination, actual enrollment of four, no results posted, and the study record’s investigational/non-FDA-approved description.
- Drugs@FDA: FDA-Approved Drugs U.S. Food and Drug Administration · Official U.S. regulatory database. Supports: Official source describing the Drugs@FDA approved-drug database and its scope; supports cautious wording that no Adipotide approval was verified in reviewed sources, not a definitive determination about the exact supplier vial.